WHO Grade III Glioma Recruiting Phase 1 Trials for Selinexor (DB11942)

IndicationStatusPhase
DBCOND0089571 (WHO Grade III Glioma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02323880Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade GliomasTreatment